Status:

COMPLETED

Reducing Side-effects of Autologous Skin Tissue Harvesting

Lead Sponsor:

Massachusetts General Hospital

Conditions:

Scar

Eligibility:

All Genders

18-50 years

Phase:

EARLY_PHASE1

Brief Summary

The investigators are doing this research study to learn about how the skin heals after many microscopic skin biopsies are collected. Skin-grafting is a life-saving procedure for people with large ar...

Detailed Description

It will take you about 8 weeks to complete this research study. During this time, the investigators will ask you to make up to 7 study visits to MGH.

Eligibility Criteria

Inclusion

  • Healthy adults (\>18 years old) scheduled to undergo elective abdominoplasty surgery at MGH, male or female.
  • Willingness to participate in the study
  • Willingness to undergo biopsies of full-thickness skin tissue from the pre-abdominoplasty skin, and have the biopsy sites marked by tattoos.
  • Informed consent agreement signed by the subject
  • Willingness to follow the treatment and follow-up schedules, and post treatment care requirements
  • Willingness to not use topical or systemic (oral) anti-scarring or anti-inflammatory\* medications during the study period.

Exclusion

  • Subjects who are immunocompromised or immunosuppressed\*
  • Subject is unable to comply with treatment, home care or follow-up visits
  • Subject has an infection or other dermatologic condition in the area to be treated
  • Subjects with a personal or family history of keloid formation.
  • Subjects with pre-existing scars, tattoos, birthmarks, or other physical features in the area to be treated, such that the experimental outcome may be confounded.
  • Subjects with a history of coagulopathy, or are taking anticoagulants
  • Subjects taking daily oral aspirin.
  • Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.
  • Subjects with any contraindications for elective abdominoplasty, as determined by their treating plastic surgeon and/or pre-op anesthesiologist.
  • Subjects with current drug or alcohol addiction.
  • Subjects who are pregnant and/or breastfeeding
  • Subjects with tape adhesive allergies
  • Subjects with known allergies to injectable lidocaine or other topical anesthetics
  • Subjects with uncontrolled or unstable chronic disease such as diabetes, hepatitis, hypertension, etc.
  • Subjects taking oral corticosteroids or topical steroids on the study area.
  • Subjects using prescription or over-the-counter medication or cosmetics containing: retinoids, glycolic acid, salicylic acid or any other remedies that might affect the healing process. (Non-medicated moisturizers are ok).
  • Subjects enrolled in other clinical studies taking any unknown or not-FDA approved medications.
  • Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
  • Notes:
  • \*About Anti-Inflammatory Medication and Immune Status The inflammatory response associated with tissue wounding is known to have substantial effects on the process of scarring, therefore all subjects who are immunocompromised, or undergoing anti-inflammatory/immunosuppressive therapies will be excluded from the study. All new medication should be reported to study doctor before each visit.

Key Trial Info

Start Date :

June 1 2016

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2019

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT02234193

Start Date

June 1 2016

End Date

March 1 2019

Last Update

January 14 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Wellman Center for Photomedicine, Massachusetts General Hospital

Boston, Massachusetts, United States, 02114